Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

Trial Details

NCT ID
NCT05795244
Phase
PHASE2
Sponsor
Yonsei University
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Nivolumab
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Explicit and voluntary consent to participation in the trial obtained by signing and dating a consent form that clearly and completely describes th…
  • Sex: female
  • Age (at the time of informed consent): 20 years and older
  • Subjects with histologically-or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed Mullerian Tumor)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →